Omkar Speciality Chemicals is planning to invest INR250m ($4.67m) to expand the production capacity from current 1,700 to 1,950 tons at its active pharmaceutical ingredient (API) facility in Badlapur, Maharashtra, India.
Omkar Speciality Chemicals chairman and managing director Pravin Herlekar was quoted by business-standard as saying that though some high-end molecules are ready for commercialization, the company is facing capacity constraints.
"There is tremendous pressure from customers as well, both domestic and global, for supply of products," Herlekar added.
"Work on the Badlapur expansion has already begun and we expect to start commercial production in eight to nine months from now.
"Having a stronghold in Hyderabad, a hub of pharmaceutical and biotech industry, we are considering having a manufacturing base here via the inorganic growth route."
The company said its $4.67m 2,800-tons plant, which will manufacture intermediates for anti-cholesterol, anti-depression and cardio-vascular drugs, coming up on the Mumbai-Goa Highway will commence its operations in October 2012.
